# Dose-Effect of S-Tenatoprazole-Na(STU-Na) 30 mg, 60 mg, 90 mg and 120 mg in Healthy Volunteers

> **NCT00284908** · PHASE1 · COMPLETED · sponsor: **STEBA France** · enrollment: 32 (actual)

## Conditions studied

- Esophagitis
- Gastroesophageal Reflux
- Stomach Ulcer
- Duodenal Ulcer

## Interventions

- **DRUG:** S-Tenatoprazole-Na (STU-Na)

## Key facts

- **NCT ID:** NCT00284908
- **Lead sponsor:** STEBA France
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09
- **Primary completion:** 2006-11
- **Final completion:** 2006-11
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2008-03-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00284908

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00284908, "Dose-Effect of S-Tenatoprazole-Na(STU-Na) 30 mg, 60 mg, 90 mg and 120 mg in Healthy Volunteers". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00284908. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*